QUEST DIAGNOSTICS INC
DGXNYSE · SIC 8071
$210.68
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↑ +28.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$23.6B
Enterprise Value
$28.9B
P/E
23.3
P/S
2.1
P/B
3.2
EV/EBITDA
13.2
PEG
7.4
FCF Yield
5.6%
Dividend Yield
1.6%
Revenue (TTM)
$11.3B
Net Income (TTM)
$1.0B
Free Cash Flow (TTM)
$1.3B
Gross Margin
—
Operating Margin
14.3%
Net Margin
9.1%
ROE
13.9%
ROIC
9.7%
Debt / Equity
0.8
Net Cash
-$5.3B
Return 1Y
+27.5%
Company profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic info services. It also provides risk assessment services for life insurance industry; and healthcare organizations and clinicians robust information technology solutions.
- CEO
- James E. Davis
- Sector
- Services
- Industry
- Healthcare
- Employees
- 49,000
- Headquarters
- New Jersey
- Website
- questdiagnostics.com
Management & directors
- Kuppusamy KarthikSVP, Clinical Solutions
- Davis J. E.CEO and President
- Delaney Mark ESVP & Chief Commercial Officer
- Plewman PatrickSVP for Diagnostic Services
- Samad Samer AbdulExecutive Vice President & CFO
- Doherty Catherine T.EVP, Regional Businesses
- Prevoznik Michael ESVP & General Counsel
- Deppe Michael JSVP, Corp. Controller & CAO
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-21
DGX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.9B↑ +9.2%
Diluted EPS$2.24↑ +15.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.4B | $10.8B | $9.9B | $9.3B | $9.9B | $11.0B |
| Gross profit | $3.6B | — | — | — | — | — |
| Operating income | $2.0B | $2.4B | $1.4B | $1.3B | $1.3B | $1.6B |
| Net income | $1.4B | $2.0B | $946.0M | $854.0M | $871.0M | $992.0M |
| Diluted EPS | $10.47 | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 |
| Operating cash flow | $2.0B | $2.2B | $1.7B | $1.3B | $1.3B | $1.9B |
| Free cash flow | $1.6B | $1.8B | $1.3B | $864.0M | $909.0M | $1.4B |
| Gross margin | 38.5% | — | — | — | — | — |
| Operating margin | 20.9% | 22.1% | 14.4% | 13.6% | 13.6% | 14.1% |
| Net margin | 15.2% | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4B | $2.5B | $2.6B | $2.7B | $2.8B | $2.8B | $2.8B | $2.9B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $355.0M | $330.0M | $361.0M | $346.0M | $438.0M | $386.0M | $386.0M | $399.0M |
| Net income | $229.0M | $226.0M | $222.0M | $220.0M | $282.0M | $245.0M | $245.0M | $252.0M |
| Diluted EPS | $2.03 | $1.99 | $1.95 | $1.94 | $2.47 | $2.16 | $2.18 | $2.24 |
| Operating cash flow | $360.0M | $356.0M | $464.0M | $314.0M | $544.0M | $563.0M | $465.0M | $278.0M |
| Free cash flow | $268.0M | $250.0M | $341.0M | $197.0M | $436.0M | $419.0M | $307.0M | $164.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 14.8% | 13.3% | 13.8% | 13.0% | 15.9% | 13.7% | 13.8% | 13.8% |
| Net margin | 9.6% | 9.1% | 8.5% | 8.3% | 10.2% | 8.7% | 8.7% | 8.7% |
Company news
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-04 | KUPPUSAMY KARTHIK· SVP, Clinical Solutions | Sale | 8,147 | $200.00 | $1.6M | filing |
| 2026-06-04 | KUPPUSAMY KARTHIK· SVP, Clinical Solutions | Option exercise | 4,827 | $121.81 | $587,952.74 | filing |
| 2026-06-04 | KUPPUSAMY KARTHIK· SVP, Clinical Solutions | Option exercise | 3,320 | $127.73 | $424,047.00 | filing |
| 2026-06-01 | Davis J. E.· CEO and President | Sale | 10,000 | $194.14 | $1.9M | filing |
| 2026-05-20 | MAIN TIMOTHY L | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | WENTWORTH TIMOTHY C | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | RING TIMOTHY M | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | Lassiter Wright III | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | MORRISON DENISE M | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | PFEIFFER GARY M | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | Doi Tracey | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | CARTER ROBERT B | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | Gregg Vicky B | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-05-20 | Diaz Luis | Award | 1,142 | $0.00 | $0.00 | filing |
| 2026-04-20 | SAMAD SAMER ABDUL· Executive Vice President & CFO | Award | 108 | $194.70 | $21,027.38 | filing |
| 2026-04-20 | Gregg Vicky B | Award | 68 | $194.70 | $13,239.46 | filing |
| 2026-04-20 | Plewman Patrick· SVP for Diagnostic Services | L | 49 | $194.70 | $9,540.25 | filing |
| 2026-04-20 | KUPPUSAMY KARTHIK· SVP, Clinical Solutions | L | 39 | $194.70 | $7,593.26 | filing |
| 2026-04-20 | DELANEY MARK E· SVP & Chief Commercial Officer | L | 37 | $194.70 | $7,203.75 | filing |
| 2026-04-20 | CARTER ROBERT B | L | 7 | $194.70 | $1,362.89 | filing |
| 2026-04-20 | Lassiter Wright III | L | 6 | $194.70 | $1,168.19 | filing |
| 2026-03-09 | WENTWORTH TIMOTHY C | Award | 215 | $0.00 | $0.00 | filing |
| 2026-03-05 | Doherty Catherine T.· EVP, Regional Businesses | Sale | 5,558 | $206.21 | $1.1M | filing |
| 2026-03-05 | PREVOZNIK MICHAEL E· SVP & General Counsel | Sale | 3,878 | $206.21 | $799,682.38 | filing |
| 2026-03-05 | Plewman Patrick· SVP for Diagnostic Services | Sale | 2,855 | $206.21 | $588,729.55 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.